Jiangsu Hualan New Pharmaceutical MaterialLtd Third Quarter 2024 Earnings: EPS: CN¥0.12 (vs CN¥0.22 in 3Q 2023)

Simply Wall St · 10/25 22:14

Jiangsu Hualan New Pharmaceutical MaterialLtd (SZSE:301093) Third Quarter 2024 Results

Key Financial Results

  • Revenue: CN¥139.1m (down 7.8% from 3Q 2023).
  • Net income: CN¥15.3m (down 48% from 3Q 2023).
  • Profit margin: 11% (down from 19% in 3Q 2023). The decrease in margin was primarily driven by lower revenue.
  • EPS: CN¥0.12 (down from CN¥0.22 in 3Q 2023).
earnings-and-revenue-growth
SZSE:301093 Earnings and Revenue Growth October 25th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Jiangsu Hualan New Pharmaceutical MaterialLtd Earnings Insights

Looking ahead, revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in China.

Performance of the Chinese Medical Equipment industry.

The company's shares are up 5.9% from a week ago.

Risk Analysis

Before you take the next step you should know about the 1 warning sign for Jiangsu Hualan New Pharmaceutical MaterialLtd that we have uncovered.